Dr. Jeffrey Weber describes the organ-specific side effects that can occur in a patient on checkpoint inhibitors.
Jeffrey Weber, MD, PhD, from NYU Langone Perlmutter Cancer Center explains the different organ-specific side effects that can occur when a patient is on checkpoint inhibitors. These toxicities can progress quickly and to fatal levels; therefore, patients need careful attention.
For example, an increase in pancreas function can present without any symptoms and requires monitoring of the patient’s lab results. Inflammation in the lungs can become pneumonitis, which can become fatal if not caught in time.
Patients With uHCC Who Experience irAEs With Tremelimumab/Durvalumab Achieve Numerical Improvements in OS
Adding Ribociclib to Endocrine Therapy Yields 25% Relative Reduction in Risk of Invasive Disease In Patients With HR+/HER2– Early Breast Cancer
Simple Hysterectomy May Replace Radical Hysterectomy as Standard of Care in Low-Risk, Early-Stage Cervical Cancer
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
2 Clarke Drive
Cranbury, NJ 08512